PHAXIAM TX news, videos and press releases
For more news please use our advanced search feature.
PHAXIAM TX - More news...
PHAXIAM TX - More news...
- PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024
- Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2024
- Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024
- PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
- Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
- PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
- PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
- PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
- Monthly information related to total number of voting rights and shares composing the share capital - November 30, 2023
- Monthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023
- PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
- Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2023
- Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
- ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
- ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023
- ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
- ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023
- Monthly information related to total number of voting rights and shares composing the share capital _April 30, 2023
- Monthly information related to total number of voting rights and shares composing the share capital _March 31, 2023
- ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022
- Monthly information related to total number of voting rights and shares composing the share capital _January 31, 2023
- Monthly information related to total number of voting rights and shares composing the share capital _December 31, 2022
- Monthly information related to total number of voting rights and shares composing the share capital _October 30, 2022
- ERYTECH Announces Receipt of Nasdaq Notice
- Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2022
- ERYTECH Provides Regulatory Update
- Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 2022
- Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2022.
- ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022
- ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar